Vidarbha News

Antibiotics Market is Expected to Hit USD 50.37 Billion by 2025, Growing at a CAGR of 2.1%

 Breaking News
  • No posts were found

Antibiotics Market is Expected to Hit USD 50.37 Billion by 2025, Growing at a CAGR of 2.1%

September 01
13:48 2019
Antibiotics Market is Expected to Hit USD 50.37 Billion by 2025, Growing at a CAGR of 2.1%

Antibiotics Market
Increased consumption of antibiotics in low- & middle-income countries worldwide play a major role in the growth of the antibiotics market. Furthermore, rise in prevalence of infectious diseases is expected to boost the market growth in the coming years

Allied Market Research is a class of Antibiotics Market (beta-lactam and beta-lactamase inhibitors (penicillin, cephalosporin, carbapenem, monobactam), quinolones, macrolides, etc.), drug discovery origin (natural, semi-synthetic and synthetic) Published the report of the title Activity spectrum (wide-spectrum antibiotic and narrow-spectrum antibiotic) and administration route (oral, intravenous, other): global opportunity analysis and industry forecast, 2018-2025. The report provides a detailed analysis of winning strategies, drivers and opportunities, key market segments, competitive environment, and strategic developments. According to the report, the Global Antibiotic Market is expected to generate $ 50.37 billion by 2025 from $ 42.23 billion in 2017, at a 2.1% CAGR.

 Increasing utilization of antibiotics in low and middle-income countries (LMICs) due to high incidence of severe infections, high capital allocation for R&D activities by biotech companies, and supportive norms and regulations drive the growth of the market. However, development of antibiotic resistance and rise in drug approval costs hinder the market growth. Conversely, discovery of advanced prospect molecules and innovative combination therapies for the treatment of antibiotic-resistant microbial infections would create opportunities for the market in future.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/5072

Beta lactam and beta lactamase inhibitors segment to maintain its dominance by 2025 

The beta lactam and beta lactamase inhibitors segment contributed nearly two-thirds of the total market share in 2017 and is expected to maintain its dominance by 2025. This is due to rise in demand for its effectiveness in treating Gram-positive & Gram-negative bacteria as well as use in the treatment of broad-spectrum of infections. However, quinolones segment would register the fastest CAGR of 4.3% from 2018 to 2025, owing to their characteristics such as remarkable oral bioavailability, good tissue penetration, and high broad-spectrum bactericidal activity, especially in new generation quinolones. The report also analyzes macrolides and others.

Semisynthetic segment to lead throughout the forecast period 

The semisynthetic segment accounted for more than one-third of the total market share in 2017 and will continue to maintain its lead by 2025. This is due to the enhanced coverage and efficacy against a wide range of organisms as well as ease in administration and cost effectiveness as compared to other antibiotics. However, the synthetic segment would register the fastest CAGR of 2.7% from 2018 to 2025 due to high demand for synthetic membrane-targeted antibiotics, broad spectrum activity, rapid bactericidal activity, no cross-resistance with existing antibiotics, and low probability of developing resistance. The report also discusses antibiotics of natural origin.

Broad-spectrum antibiotics segment to be lucrative by 2025 

Broad-spectrum antibiotics segment contributed more than two-thirds of the total market share in 2017. This segment would dominate by 2025, registering the fastest CAGR of 2.4% from 2018 to 2025. This is attributed to the growing demand for broad-spectrum antibiotics to curb widespread antimicrobial resistance. The research also discusses narrow-spectrum antibiotics.

For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/5072

Intravenous segment to dominate in terms of revenue during the forecast period  

Intravenous route of administration segment accounted for nearly half of the total market share in 2017, owing to the rise in incidence of severe infections, which requires intravenous antibiotics for reaching the tissues faster and achieving higher concentrations as compared to oral antibiotics. This segment would maintain its lead position by 2025. However, the oral segment would grow at the highest CAGR of 2.5% from 2018 to 2025, owing to ease in self-administration, which results in high demand for oral drugs and reduction in hospital stay.

Asia-Pacific to register the highest revenue by 2025 

Asia-Pacific region contributed more than one-third of the total market share in 2017, owing to the burgeoning rate of antibiotics consumption, ease in availability of antibiotics, and increase in sales of antibiotics without prescription. This region would continue to dominate throughout the forecast period. However, LAMEA region would grow at the fastest CAGR of 3.5% from 2018 to 2025. This is due to easy of availability and relaxed legislations or restrictions on their usage in this region.

Leading market players 

The key market players analyzed in the report include Abbott Laboratories, F.Hoffmann-La Roche Ltd., Allergan Plc., Merck & Co. Inc., GlaxoSmithKline plc, Novartis International AG (Sandoz), Mylan N.V., Sanofi, Pfizer Inc., and Teva Pharmaceutical Industries Ltd. They have implemented various strategies such as expansions, mergers & acquisitions, joint ventures, partnerships, collaborations, and others to achieve a strong position in the industry.

Similar Reports: 

3D Printed Drugs Market – Global Opportunity Analysis and Industry Forecast, 2017-2030

BCG Vaccine Market – Global Opportunity Analysis and Industry Forecast, 2017-2023

 

About Us 

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

 

Media Contact
Company Name: Allied Market Research
Contact Person: David Correa
Email: Send Email
Phone: +1-800-792-5285
Address:5933 NE Win Sivers Drive #205, Portland, OR 97220
City: Portland
State: United States
Country: United States
Website: www.alliedmarketresearch.com/antibiotics-market

Categories